However, specific GLP-1 receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors have a favourable effect on some CV outcomes in T2DM patients at increased CV risk on metformin-based background therapy [87]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.